,title,publish_time,journal,url,abstract,doi,cord_uid,words
29355,Companion diagnostics: emerging strategies and issues in pharmaceutical development.,2012,Expert review of molecular diagnostics,https://doi.org/10.1586/erm.12.49; https://www.ncbi.nlm.nih.gov/pubmed/22845476/,"This article summarizes the broad messages from pharmaceutical and diagnostic companies on the collaborations required to support companion diagnostics. Since the groundbreaking herceptin HER2 diagnostic model in 1998, it has taken until 2011 for the US FDA to issue a draft guidance document, which was then immediately followed with approvals for two new drugs and their companion diagnostics. This conference summarized the current state of thinking in new projects and innovative technologies in pharmaceutical and diagnostic codevelopment. Attitudes are slowly changing and collaborations are rapidly ensuing, although the alignment between pharmaceutical and diagnostic understanding of value, timelines, outcomes and impact is difficult and remains a contentious area. The value of this conference has been to address these issues.",10.1586/erm.12.49,mwzhy7lb,"['This', 'article', 'summarizes', 'the', 'broad', 'messages', 'from', 'pharmaceutical', 'and', 'diagnostic', 'companies', 'on', 'the', 'collaborations', 'required', 'to', 'support', 'companion', 'diagnostics', 'Since', 'the', 'groundbreaking', 'herceptin', 'HER2', 'diagnostic', 'model', 'in', '1998', 'it', 'has', 'taken', 'until', '2011', 'for', 'the', 'US', 'FDA', 'to', 'issue', 'a', 'draft', 'guidance', 'document', 'which', 'was', 'then', 'immediately', 'followed', 'with', 'approvals', 'for', 'two', 'new', 'drugs', 'and', 'their', 'companion', 'diagnostics', 'This', 'conference', 'summarized', 'the', 'current', 'state', 'of', 'thinking', 'in', 'new', 'projects', 'and', 'innovative', 'technologies', 'in', 'pharmaceutical', 'and', 'diagnostic', 'codevelopment', 'Attitudes', 'are', 'slowly', 'changing', 'and', 'collaborations', 'are', 'rapidly', 'ensuing', 'although', 'the', 'alignment', 'between', 'pharmaceutical', 'and', 'diagnostic', 'understanding', 'of', 'value', 'timelines', 'outcomes', 'and', 'impact', 'is', 'difficult', 'and', 'remains', 'a', 'contentious', 'area', 'The', 'value', 'of', 'this', 'conference', 'has', 'been', 'to', 'address', 'these', 'issues', '']"
30780,Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens.,2020-04-27,Journal of clinical microbiology,https://doi.org/10.1128/jcm.00743-20; https://www.ncbi.nlm.nih.gov/pubmed/32341143/,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Modified CDC), the Simplexa COVID-19 Direct (Diasorin Molecular), GenMark ePlex SARS-CoV-2 assay (GenMark) and the Hologic Panther Fusion® SARS-CoV-2 assay (Hologic). This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made.",10.1128/jcm.00743-20,b0qtzzac,"['Severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'the', 'novel', 'human', 'coronavirus', 'that', 'causes', 'coronavirus', 'disease', '2019', 'COVID', '19', 'was', 'first', 'discovered', 'in', 'December', '2019', 'as', 'the', 'cause', 'of', 'an', 'outbreak', 'of', 'pneumonia', 'in', 'the', 'city', 'of', 'Wuhan', 'Hubei', 'province', 'China', 'The', 'clinical', 'presentation', 'of', 'COVID', '19', 'is', 'fairly', 'non', 'specific', 'and', 'symptoms', 'overlap', 'with', 'other', 'seasonal', 'respiratory', 'infections', 'concurrently', 'circulating', 'in', 'the', 'population', 'Furthermore', 'it', 'is', 'estimated', 'that', 'up', 'to', '80', 'of', 'infected', 'individuals', 'experience', 'mild', 'symptoms', 'or', 'are', 'asymptomatic', 'confounding', 'efforts', 'to', 'reliably', 'diagnose', 'COVID', '19', 'empirically', 'To', 'support', 'infection', 'control', 'measures', 'there', 'is', 'an', 'urgent', 'need', 'for', 'rapid', 'and', 'accurate', 'molecular', 'diagnostics', 'to', 'identify', 'COVID', '19', 'positive', 'patients', 'In', 'the', 'present', 'study', 'we', 'have', 'evaluated', 'the', 'analytical', 'sensitivity', 'and', 'clinical', 'performance', 'of', 'four', 'SARS', 'CoV', '2', 'molecular', 'diagnostic', 'assays', 'granted', 'Emergency', 'Use', 'Authorization', 'by', 'the', 'FDA', 'using', 'nasopharyngeal', 'swabs', 'from', 'symptomatic', 'patients', 'the', 'New', 'York', 'SARS', 'CoV', '2', 'Real', 'time', 'Reverse', 'Transcriptase', 'RT', 'PCR', 'Diagnostic', 'Panel', 'Modified', 'CDC', 'the', 'Simplexa', 'COVID', '19', 'Direct', 'Diasorin', 'Molecular', 'GenMark', 'ePlex', 'SARS', 'CoV', '2', 'assay', 'GenMark', 'and', 'the', 'Hologic', 'Panther', 'Fusion', 'SARS', 'CoV', '2', 'assay', 'Hologic', 'This', 'information', 'is', 'crucial', 'for', 'both', 'laboratories', 'and', 'clinical', 'teams', 'as', 'decisions', 'on', 'which', 'testing', 'platform', 'to', 'implement', 'are', 'made', '']"
39729,United States FDA's emergency use authorization of Ebola virus diagnostics: current impact and lessons for the future.,2015,Expert review of molecular diagnostics,https://doi.org/10.1586/14737159.2015.1077117; https://www.ncbi.nlm.nih.gov/pubmed/26394699/,"The Ebola outbreak that took hold in West Africa in 2014 outran the epidemic response capacity of many organizations. Five months after the epidemic was first declared, there were still only two laboratories in West Africa with the capacity to confirm Ebola virus infection. In the summer of 2014, before the first case of imported Ebola occurred in the USA, the US FDA announced it would issue Emergency Use Authorizations for Ebola virus in vitro diagnostics to speed their availability. Between October 2014 and March 2015, the FDA issued Emergency Use Authorizations for nine diagnostic products. The actions of the FDA not only allowed nationwide deployment of Ebola virus testing capacity in the USA but also established an attractive regulatory goalpost for companies developing assays for use in West Africa. Here, we comment on the diagnostic assays for which the FDA has issued emergency authorizations and their fitness for purpose.",10.1586/14737159.2015.1077117,qb4zizor,"['The', 'Ebola', 'outbreak', 'that', 'took', 'hold', 'in', 'West', 'Africa', 'in', '2014', 'outran', 'the', 'epidemic', 'response', 'capacity', 'of', 'many', 'organizations', 'Five', 'months', 'after', 'the', 'epidemic', 'was', 'first', 'declared', 'there', 'were', 'still', 'only', 'two', 'laboratories', 'in', 'West', 'Africa', 'with', 'the', 'capacity', 'to', 'confirm', 'Ebola', 'virus', 'infection', 'In', 'the', 'summer', 'of', '2014', 'before', 'the', 'first', 'case', 'of', 'imported', 'Ebola', 'occurred', 'in', 'the', 'USA', 'the', 'US', 'FDA', 'announced', 'it', 'would', 'issue', 'Emergency', 'Use', 'Authorizations', 'for', 'Ebola', 'virus', 'in', 'vitro', 'diagnostics', 'to', 'speed', 'their', 'availability', 'Between', 'October', '2014', 'and', 'March', '2015', 'the', 'FDA', 'issued', 'Emergency', 'Use', 'Authorizations', 'for', 'nine', 'diagnostic', 'products', 'The', 'actions', 'of', 'the', 'FDA', 'not', 'only', 'allowed', 'nationwide', 'deployment', 'of', 'Ebola', 'virus', 'testing', 'capacity', 'in', 'the', 'USA', 'but', 'also', 'established', 'an', 'attractive', 'regulatory', 'goalpost', 'for', 'companies', 'developing', 'assays', 'for', 'use', 'in', 'West', 'Africa', 'Here', 'we', 'comment', 'on', 'the', 'diagnostic', 'assays', 'for', 'which', 'the', 'FDA', 'has', 'issued', 'emergency', 'authorizations', 'and', 'their', 'fitness', 'for', 'purpose', '']"
44398,Syndromic Panel-Based Testing in Clinical Microbiology.,2018,Clinical microbiology reviews,https://doi.org/10.1128/cmr.00024-17; https://www.ncbi.nlm.nih.gov/pubmed/29142077/,"The recent development of commercial panel-based molecular diagnostics for the rapid detection of pathogens in positive blood culture bottles, respiratory specimens, stool, and cerebrospinal fluid has resulted in a paradigm shift in clinical microbiology and clinical practice. This review focuses on U.S. Food and Drug Administration (FDA)-approved/cleared multiplex molecular panels with more than five targets designed to assist in the diagnosis of bloodstream, respiratory tract, gastrointestinal, or central nervous system infections. While these panel-based assays have the clear advantages of a rapid turnaround time and the detection of a large number of microorganisms and promise to improve health care, they present certain challenges, including cost and the definition of ideal test utilization strategies (i.e., optimal ordering) and test interpretation.",10.1128/cmr.00024-17,gsprsbug,"['The', 'recent', 'development', 'of', 'commercial', 'panel', 'based', 'molecular', 'diagnostics', 'for', 'the', 'rapid', 'detection', 'of', 'pathogens', 'in', 'positive', 'blood', 'culture', 'bottles', 'respiratory', 'specimens', 'stool', 'and', 'cerebrospinal', 'fluid', 'has', 'resulted', 'in', 'a', 'paradigm', 'shift', 'in', 'clinical', 'microbiology', 'and', 'clinical', 'practice', 'This', 'review', 'focuses', 'on', 'U', 'S', 'Food', 'and', 'Drug', 'Administration', 'FDA', 'approved', 'cleared', 'multiplex', 'molecular', 'panels', 'with', 'more', 'than', 'five', 'targets', 'designed', 'to', 'assist', 'in', 'the', 'diagnosis', 'of', 'bloodstream', 'respiratory', 'tract', 'gastrointestinal', 'or', 'central', 'nervous', 'system', 'infections', 'While', 'these', 'panel', 'based', 'assays', 'have', 'the', 'clear', 'advantages', 'of', 'a', 'rapid', 'turnaround', 'time', 'and', 'the', 'detection', 'of', 'a', 'large', 'number', 'of', 'microorganisms', 'and', 'promise', 'to', 'improve', 'health', 'care', 'they', 'present', 'certain', 'challenges', 'including', 'cost', 'and', 'the', 'definition', 'of', 'ideal', 'test', 'utilization', 'strategies', 'i', 'e', 'optimal', 'ordering', 'and', 'test', 'interpretation', '']"
47874,"Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19.",2020-04-17,Journal of clinical microbiology,https://doi.org/10.1128/jcm.00760-20; https://www.ncbi.nlm.nih.gov/pubmed/32303564/,"Dozens of in vitro diagnostics (IVDs) have received emergency use authorization (EUA) from the U.S. Food & Drug Administration (FDA) for the detection of SARS-CoV-2, but little has been studied to determine how well these assays perform using clinical specimens.….",10.1128/jcm.00760-20,m52m9f18,"['Dozens', 'of', 'in', 'vitro', 'diagnostics', 'IVDs', 'have', 'received', 'emergency', 'use', 'authorization', 'EUA', 'from', 'the', 'U', 'S', 'Food', 'Drug', 'Administration', 'FDA', 'for', 'the', 'detection', 'of', 'SARS', 'CoV', '2', 'but', 'little', 'has', 'been', 'studied', 'to', 'determine', 'how', 'well', 'these', 'assays', 'perform', 'using', 'clinical', 'specimens', '']"
53645,Comparison of the Xpert Flu/RSV XC and Xpress Flu/RSV Assays.,2018,Journal of clinical microbiology,https://doi.org/10.1128/jcm.00278-18; https://www.ncbi.nlm.nih.gov/pubmed/29769281/,"Molecular diagnostics for influenza and respiratory syncytial virus (RSV) have become commonplace, and various tests and systems have been cleared by the FDA for use in the United States. We performed a retrospective study to compare the Cepheid Xpress Flu/RSV assay with the Xpert Flu/RSV XC assay, using laboratory-developed tests (LDTs) as the reference method. The Xpress assay was 100% accurate compared to LDTs, whereas the Xpert Flu/RSV XC assay was 96.0% accurate. The Xpress test was determined to be faster and more sensitive than the XC assay.",10.1128/jcm.00278-18,nlvwlk4d,"['Molecular', 'diagnostics', 'for', 'influenza', 'and', 'respiratory', 'syncytial', 'virus', 'RSV', 'have', 'become', 'commonplace', 'and', 'various', 'tests', 'and', 'systems', 'have', 'been', 'cleared', 'by', 'the', 'FDA', 'for', 'use', 'in', 'the', 'United', 'States', 'We', 'performed', 'a', 'retrospective', 'study', 'to', 'compare', 'the', 'Cepheid', 'Xpress', 'Flu', 'RSV', 'assay', 'with', 'the', 'Xpert', 'Flu', 'RSV', 'XC', 'assay', 'using', 'laboratory', 'developed', 'tests', 'LDTs', 'as', 'the', 'reference', 'method', 'The', 'Xpress', 'assay', 'was', '100', 'accurate', 'compared', 'to', 'LDTs', 'whereas', 'the', 'Xpert', 'Flu', 'RSV', 'XC', 'assay', 'was', '96', '0', 'accurate', 'The', 'Xpress', 'test', 'was', 'determined', 'to', 'be', 'faster', 'and', 'more', 'sensitive', 'than', 'the', 'XC', 'assay', '']"
76045,Clinical assessment and validation of a rapid and sensitive SARS-CoV-2 test using reverse-transcription loop-mediated isothermal amplification,2020-05-18,,http://medrxiv.org/cgi/content/short/2020.05.12.20095638v1?rss=1,"Amid the enduring COVID-19 pandemic, there is an urgent need for expanded access to rapid and sensitive SARS-CoV-2 testing worldwide. Here we present a simple clinical workflow that uses a sensitive and highly specific colorimetric reverse-transcription loop-mediated isothermal amplification (RT-LAMP) to detect SARS-CoV-2 and takes forty minutes from sample collection to result. This test requires no specialized equipment and costs a few dollars per sample. Nasopharyngeal samples collected in saline were added either directly (unprocessed) to RT-LAMP reactions or first inactivated by a combined chemical and heat treatment step to inhibit RNases and lyse virions and human cells. The specimens were then amplified with two SARS-CoV-2-specific primer sets and an internal specimen control; the resulting color change was visually interpreted. While direct addition of unprocessed specimens to RT-LAMP reactions could reliably detect samples with abundant SARS-CoV-2, the assay sensitivity markedly increased after the addition of an inactivation step. In 62 clinical samples with a wide range of SARS-CoV-2 nucleic acid concentrations, the assay had 87.5% sensitivity and 100% specificity with a limit of detection at least 25 copies/L, making it an ideal test to rule in infection. To increase sensitivity, samples that tested negative for SARS-CoV-2 by direct sample addition could be reflexed to a purification step, to increase the effective per-reaction sample input volume. In 40 purified samples, the assay yielded a 90% sensitivity and 100% specificity, with a limit of detection comparable to commercially available real-time PCR-based diagnostics that have received Emergency Use Authorization (EUA) from the FDA. This test for SARS-CoV-2 can be performed in a range of settings for a fraction of the price of other available tests, with limited equipment, and without relying on over-burdened supply chains to increase overall testing capacity.",10.1101/2020.05.12.20095638,m7gzgtil,"['Amid', 'the', 'enduring', 'COVID', '19', 'pandemic', 'there', 'is', 'an', 'urgent', 'need', 'for', 'expanded', 'access', 'to', 'rapid', 'and', 'sensitive', 'SARS', 'CoV', '2', 'testing', 'worldwide', 'Here', 'we', 'present', 'a', 'simple', 'clinical', 'workflow', 'that', 'uses', 'a', 'sensitive', 'and', 'highly', 'specific', 'colorimetric', 'reverse', 'transcription', 'loop', 'mediated', 'isothermal', 'amplification', 'RT', 'LAMP', 'to', 'detect', 'SARS', 'CoV', '2', 'and', 'takes', 'forty', 'minutes', 'from', 'sample', 'collection', 'to', 'result', 'This', 'test', 'requires', 'no', 'specialized', 'equipment', 'and', 'costs', 'a', 'few', 'dollars', 'per', 'sample', 'Nasopharyngeal', 'samples', 'collected', 'in', 'saline', 'were', 'added', 'either', 'directly', 'unprocessed', 'to', 'RT', 'LAMP', 'reactions', 'or', 'first', 'inactivated', 'by', 'a', 'combined', 'chemical', 'and', 'heat', 'treatment', 'step', 'to', 'inhibit', 'RNases', 'and', 'lyse', 'virions', 'and', 'human', 'cells', 'The', 'specimens', 'were', 'then', 'amplified', 'with', 'two', 'SARS', 'CoV', '2', 'specific', 'primer', 'sets', 'and', 'an', 'internal', 'specimen', 'control', 'the', 'resulting', 'color', 'change', 'was', 'visually', 'interpreted', 'While', 'direct', 'addition', 'of', 'unprocessed', 'specimens', 'to', 'RT', 'LAMP', 'reactions', 'could', 'reliably', 'detect', 'samples', 'with', 'abundant', 'SARS', 'CoV', '2', 'the', 'assay', 'sensitivity', 'markedly', 'increased', 'after', 'the', 'addition', 'of', 'an', 'inactivation', 'step', 'In', '62', 'clinical', 'samples', 'with', 'a', 'wide', 'range', 'of', 'SARS', 'CoV', '2', 'nucleic', 'acid', 'concentrations', 'the', 'assay', 'had', '87', '5', 'sensitivity', 'and', '100', 'specificity', 'with', 'a', 'limit', 'of', 'detection', 'at', 'least', '25', 'copies', 'L', 'making', 'it', 'an', 'ideal', 'test', 'to', 'rule', 'in', 'infection', 'To', 'increase', 'sensitivity', 'samples', 'that', 'tested', 'negative', 'for', 'SARS', 'CoV', '2', 'by', 'direct', 'sample', 'addition', 'could', 'be', 'reflexed', 'to', 'a', 'purification', 'step', 'to', 'increase', 'the', 'effective', 'per', 'reaction', 'sample', 'input', 'volume', 'In', '40', 'purified', 'samples', 'the', 'assay', 'yielded', 'a', '90', 'sensitivity', 'and', '100', 'specificity', 'with', 'a', 'limit', 'of', 'detection', 'comparable', 'to', 'commercially', 'available', 'real', 'time', 'PCR', 'based', 'diagnostics', 'that', 'have', 'received', 'Emergency', 'Use', 'Authorization', 'EUA', 'from', 'the', 'FDA', 'This', 'test', 'for', 'SARS', 'CoV', '2', 'can', 'be', 'performed', 'in', 'a', 'range', 'of', 'settings', 'for', 'a', 'fraction', 'of', 'the', 'price', 'of', 'other', 'available', 'tests', 'with', 'limited', 'equipment', 'and', 'without', 'relying', 'on', 'over', 'burdened', 'supply', 'chains', 'to', 'increase', 'overall', 'testing', 'capacity', '']"
78579,"Validation of a single-step, single-tube reverse transcription-loop-mediated isothermal amplification assay for rapid detection of SARS-CoV-2 RNA",2020-04-30,bioRxiv,https://doi.org/10.1101/2020.04.28.067363,"Introduction The SARS-CoV-2 pandemic of 2020 has resulted in unparalleled requirements for RNA extraction kits and enzymes required for virus detection, leading to global shortages. This has necessitated the exploration of alternative diagnostic options to alleviate supply chain issues. Aim To establish and validate a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the detection of SARS-CoV-2 from nasopharyngeal swabs. Methodology We used a commercial RT-LAMP mastermix from OptiGene Ltd in combination with a primer set designed to detect the CDC N1 region of the SARS-CoV-2 nucleocapsid (N) gene. A single-tube, single-step fluorescence assay was implemented whereby as little as 1 μL of universal transport medium (UTM) directly from a nasopharyngeal swab could be used as template, bypassing the requirement for RNA purification. Amplification and detection could be conducted in any thermocycler capable of holding 65°C for 30 minutes and measure fluorescence in the FAM channel at one-minute intervals. Results Assay evaluation by assessment of 157 clinical specimens previously screened by E-gene RT-qPCR revealed assay sensitivity and specificity of 87% and 100%, respectively. Results were fast, with an average time-to-positive (Tp) for 93 clinical samples of 14 minutes (SD ±7 minutes). Using dilutions of SARS-CoV-2 virus spiked into UTM, we also evaluated assay performance against FDA guidelines for implementation of emergency-use diagnostics and established a limit-of-detection of 54 Tissue Culture Infectious Dose 50 per ml (TCID50 mL−1), with satisfactory assay sensitivity and specificity. A comparison of 20 clinical specimens between four laboratories showed excellent interlaboratory concordance; performing equally well on three different, commonly used thermocyclers, pointing to the robustness of the assay. Conclusion With a simplified workflow, N1-STOP-LAMP is a powerful, scalable option for specific and rapid detection of SARS-CoV-2 and an additional resource in the diagnostic armamentarium against COVID-19. 3. Data summary The authors confirm all supporting data, code and protocols have been provided within the article or through supplementary data files.",10.1101/2020.04.28.067363,wiyvrpij,"['Introduction', 'The', 'SARS', 'CoV', '2', 'pandemic', 'of', '2020', 'has', 'resulted', 'in', 'unparalleled', 'requirements', 'for', 'RNA', 'extraction', 'kits', 'and', 'enzymes', 'required', 'for', 'virus', 'detection', 'leading', 'to', 'global', 'shortages', 'This', 'has', 'necessitated', 'the', 'exploration', 'of', 'alternative', 'diagnostic', 'options', 'to', 'alleviate', 'supply', 'chain', 'issues', 'Aim', 'To', 'establish', 'and', 'validate', 'a', 'reverse', 'transcription', 'loop', 'mediated', 'isothermal', 'amplification', 'RT', 'LAMP', 'assay', 'for', 'the', 'detection', 'of', 'SARS', 'CoV', '2', 'from', 'nasopharyngeal', 'swabs', 'Methodology', 'We', 'used', 'a', 'commercial', 'RT', 'LAMP', 'mastermix', 'from', 'OptiGene', 'Ltd', 'in', 'combination', 'with', 'a', 'primer', 'set', 'designed', 'to', 'detect', 'the', 'CDC', 'N1', 'region', 'of', 'the', 'SARS', 'CoV', '2', 'nucleocapsid', 'N', 'gene', 'A', 'single', 'tube', 'single', 'step', 'fluorescence', 'assay', 'was', 'implemented', 'whereby', 'as', 'little', 'as', '1', 'μL', 'of', 'universal', 'transport', 'medium', 'UTM', 'directly', 'from', 'a', 'nasopharyngeal', 'swab', 'could', 'be', 'used', 'as', 'template', 'bypassing', 'the', 'requirement', 'for', 'RNA', 'purification', 'Amplification', 'and', 'detection', 'could', 'be', 'conducted', 'in', 'any', 'thermocycler', 'capable', 'of', 'holding', '65', 'C', 'for', '30', 'minutes', 'and', 'measure', 'fluorescence', 'in', 'the', 'FAM', 'channel', 'at', 'one', 'minute', 'intervals', 'Results', 'Assay', 'evaluation', 'by', 'assessment', 'of', '157', 'clinical', 'specimens', 'previously', 'screened', 'by', 'E', 'gene', 'RT', 'qPCR', 'revealed', 'assay', 'sensitivity', 'and', 'specificity', 'of', '87', 'and', '100', 'respectively', 'Results', 'were', 'fast', 'with', 'an', 'average', 'time', 'to', 'positive', 'Tp', 'for', '93', 'clinical', 'samples', 'of', '14', 'minutes', 'SD', '7', 'minutes', 'Using', 'dilutions', 'of', 'SARS', 'CoV', '2', 'virus', 'spiked', 'into', 'UTM', 'we', 'also', 'evaluated', 'assay', 'performance', 'against', 'FDA', 'guidelines', 'for', 'implementation', 'of', 'emergency', 'use', 'diagnostics', 'and', 'established', 'a', 'limit', 'of', 'detection', 'of', '54', 'Tissue', 'Culture', 'Infectious', 'Dose', '50', 'per', 'ml', 'TCID50', 'mL', '1', 'with', 'satisfactory', 'assay', 'sensitivity', 'and', 'specificity', 'A', 'comparison', 'of', '20', 'clinical', 'specimens', 'between', 'four', 'laboratories', 'showed', 'excellent', 'interlaboratory', 'concordance', 'performing', 'equally', 'well', 'on', 'three', 'different', 'commonly', 'used', 'thermocyclers', 'pointing', 'to', 'the', 'robustness', 'of', 'the', 'assay', 'Conclusion', 'With', 'a', 'simplified', 'workflow', 'N1', 'STOP', 'LAMP', 'is', 'a', 'powerful', 'scalable', 'option', 'for', 'specific', 'and', 'rapid', 'detection', 'of', 'SARS', 'CoV', '2', 'and', 'an', 'additional', 'resource', 'in', 'the', 'diagnostic', 'armamentarium', 'against', 'COVID', '19', '3', 'Data', 'summary', 'The', 'authors', 'confirm', 'all', 'supporting', 'data', 'code', 'and', 'protocols', 'have', 'been', 'provided', 'within', 'the', 'article', 'or', 'through', 'supplementary', 'data', 'files', '']"
81011,Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens,2020-04-22,,http://medrxiv.org/cgi/content/short/2020.04.17.20069864v1?rss=1,"The novel human coronavirus SARS-CoV-2 was first discovered in the city of Wuhan, Hubei province, China, causing an outbreak of pneumonia in January 2020. As of April 10, 2020, the virus has rapidly disseminated to over 200 countries and territories, causing more than 1.6 million confirmed cases of COVID-19 and 97,000 deaths worldwide. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Further, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients. This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made.",10.1101/2020.04.17.20069864,2bf3xzni,"['The', 'novel', 'human', 'coronavirus', 'SARS', 'CoV', '2', 'was', 'first', 'discovered', 'in', 'the', 'city', 'of', 'Wuhan', 'Hubei', 'province', 'China', 'causing', 'an', 'outbreak', 'of', 'pneumonia', 'in', 'January', '2020', 'As', 'of', 'April', '10', '2020', 'the', 'virus', 'has', 'rapidly', 'disseminated', 'to', 'over', '200', 'countries', 'and', 'territories', 'causing', 'more', 'than', '1', '6', 'million', 'confirmed', 'cases', 'of', 'COVID', '19', 'and', '97', '000', 'deaths', 'worldwide', 'The', 'clinical', 'presentation', 'of', 'COVID', '19', 'is', 'fairly', 'non', 'specific', 'and', 'symptoms', 'overlap', 'with', 'other', 'seasonal', 'respiratory', 'infections', 'concurrently', 'circulating', 'in', 'the', 'population', 'Further', 'it', 'is', 'estimated', 'that', 'up', 'to', '80', 'of', 'infected', 'individuals', 'experience', 'mild', 'symptoms', 'or', 'are', 'asymptomatic', 'confounding', 'efforts', 'to', 'reliably', 'diagnose', 'COVID', '19', 'empirically', 'To', 'support', 'infection', 'control', 'measures', 'there', 'is', 'an', 'urgent', 'need', 'for', 'rapid', 'and', 'accurate', 'molecular', 'diagnostics', 'to', 'identify', 'COVID', '19', 'positive', 'patients', 'In', 'the', 'present', 'study', 'we', 'have', 'evaluated', 'the', 'analytical', 'sensitivity', 'and', 'clinical', 'performance', 'of', 'four', 'SARS', 'CoV', '2', 'molecular', 'diagnostic', 'assays', 'granted', 'Emergency', 'Use', 'Authorization', 'by', 'the', 'FDA', 'using', 'nasopharyngeal', 'swabs', 'from', 'symptomatic', 'patients', 'This', 'information', 'is', 'crucial', 'for', 'both', 'laboratories', 'and', 'clinical', 'teams', 'as', 'decisions', 'on', 'which', 'testing', 'platform', 'to', 'implement', 'are', 'made', '']"
138433,Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens,2020,J. clin. microbiol,,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly nonspecific, and symptoms overlap those of other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19-positive patients. In the present study, we evaluated the analytical sensitivity and clinical performance of the following four SARS-CoV-2 molecular diagnostic assays granted emergency use authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (modified CDC) assay, the Simplexa COVID-19 Direct (Diasorin Molecular) assay, GenMark ePlex SARS-CoV-2 (GenMark) assay, and the Hologic Panther Fusion SARS-CoV-2 (Hologic) assay. This information is crucial for both laboratories and clinical teams as decisions on which testing platform to implement are made.",,mg2xl68q,"['Severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'the', 'novel', 'human', 'coronavirus', 'that', 'causes', 'coronavirus', 'disease', '2019', 'COVID', '19', 'was', 'first', 'discovered', 'in', 'December', '2019', 'as', 'the', 'cause', 'of', 'an', 'outbreak', 'of', 'pneumonia', 'in', 'the', 'city', 'of', 'Wuhan', 'Hubei', 'province', 'China', 'The', 'clinical', 'presentation', 'of', 'COVID', '19', 'is', 'fairly', 'nonspecific', 'and', 'symptoms', 'overlap', 'those', 'of', 'other', 'seasonal', 'respiratory', 'infections', 'concurrently', 'circulating', 'in', 'the', 'population', 'Furthermore', 'it', 'is', 'estimated', 'that', 'up', 'to', '80', 'of', 'infected', 'individuals', 'experience', 'mild', 'symptoms', 'or', 'are', 'asymptomatic', 'confounding', 'efforts', 'to', 'reliably', 'diagnose', 'COVID', '19', 'empirically', 'To', 'support', 'infection', 'control', 'measures', 'there', 'is', 'an', 'urgent', 'need', 'for', 'rapid', 'and', 'accurate', 'molecular', 'diagnostics', 'to', 'identify', 'COVID', '19', 'positive', 'patients', 'In', 'the', 'present', 'study', 'we', 'evaluated', 'the', 'analytical', 'sensitivity', 'and', 'clinical', 'performance', 'of', 'the', 'following', 'four', 'SARS', 'CoV', '2', 'molecular', 'diagnostic', 'assays', 'granted', 'emergency', 'use', 'authorization', 'by', 'the', 'FDA', 'using', 'nasopharyngeal', 'swabs', 'from', 'symptomatic', 'patients', 'the', 'New', 'York', 'SARS', 'CoV', '2', 'Real', 'time', 'Reverse', 'Transcriptase', 'RT', 'PCR', 'Diagnostic', 'Panel', 'modified', 'CDC', 'assay', 'the', 'Simplexa', 'COVID', '19', 'Direct', 'Diasorin', 'Molecular', 'assay', 'GenMark', 'ePlex', 'SARS', 'CoV', '2', 'GenMark', 'assay', 'and', 'the', 'Hologic', 'Panther', 'Fusion', 'SARS', 'CoV', '2', 'Hologic', 'assay', 'This', 'information', 'is', 'crucial', 'for', 'both', 'laboratories', 'and', 'clinical', 'teams', 'as', 'decisions', 'on', 'which', 'testing', 'platform', 'to', 'implement', 'are', 'made', '']"
138434,Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens,2020,J. clin. microbiol,,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Modified CDC), the Simplexa COVID-19 Direct (Diasorin Molecular), GenMark ePlex SARS-CoV-2 assay (GenMark) and the Hologic Panther Fusion® SARS-CoV-2 assay (Hologic). This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made.",,78yzkodj,"['Severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'the', 'novel', 'human', 'coronavirus', 'that', 'causes', 'coronavirus', 'disease', '2019', 'COVID', '19', 'was', 'first', 'discovered', 'in', 'December', '2019', 'as', 'the', 'cause', 'of', 'an', 'outbreak', 'of', 'pneumonia', 'in', 'the', 'city', 'of', 'Wuhan', 'Hubei', 'province', 'China', 'The', 'clinical', 'presentation', 'of', 'COVID', '19', 'is', 'fairly', 'non', 'specific', 'and', 'symptoms', 'overlap', 'with', 'other', 'seasonal', 'respiratory', 'infections', 'concurrently', 'circulating', 'in', 'the', 'population', 'Furthermore', 'it', 'is', 'estimated', 'that', 'up', 'to', '80', 'of', 'infected', 'individuals', 'experience', 'mild', 'symptoms', 'or', 'are', 'asymptomatic', 'confounding', 'efforts', 'to', 'reliably', 'diagnose', 'COVID', '19', 'empirically', 'To', 'support', 'infection', 'control', 'measures', 'there', 'is', 'an', 'urgent', 'need', 'for', 'rapid', 'and', 'accurate', 'molecular', 'diagnostics', 'to', 'identify', 'COVID', '19', 'positive', 'patients', 'In', 'the', 'present', 'study', 'we', 'have', 'evaluated', 'the', 'analytical', 'sensitivity', 'and', 'clinical', 'performance', 'of', 'four', 'SARS', 'CoV', '2', 'molecular', 'diagnostic', 'assays', 'granted', 'Emergency', 'Use', 'Authorization', 'by', 'the', 'FDA', 'using', 'nasopharyngeal', 'swabs', 'from', 'symptomatic', 'patients', 'the', 'New', 'York', 'SARS', 'CoV', '2', 'Real', 'time', 'Reverse', 'Transcriptase', 'RT', 'PCR', 'Diagnostic', 'Panel', 'Modified', 'CDC', 'the', 'Simplexa', 'COVID', '19', 'Direct', 'Diasorin', 'Molecular', 'GenMark', 'ePlex', 'SARS', 'CoV', '2', 'assay', 'GenMark', 'and', 'the', 'Hologic', 'Panther', 'Fusion', 'SARS', 'CoV', '2', 'assay', 'Hologic', 'This', 'information', 'is', 'crucial', 'for', 'both', 'laboratories', 'and', 'clinical', 'teams', 'as', 'decisions', 'on', 'which', 'testing', 'platform', 'to', 'implement', 'are', 'made', '']"
143733,Sensitive Commercial NASBA Assay for the Detection of Respiratory Syncytial Virus in Clinical Specimen,2007-12-26,PLoS One,https://www.ncbi.nlm.nih.gov/pubmed/18159240/,"The aim of the study was to evaluate the usability of three diagnostic procedures for the detection of respiratory syncytial virus in clinical samples. Therefore, the FDA cleared CE marked NOW® RSV ELISA, the NucliSENS® EasyQ RSV A+B NASBA, and a literature based inhouse RT-PCR protocol were compared for their relative sensitivities. Thereby, NASBA turned out to be the most sensitive method with a total number of 80 RSV positive samples out of a cohort of 251 nasopharyngeal washings from patients suffering from clinical symptoms, followed by the inhouse RT-PCR (62/251) and ELISA (52/251). Thus, NASBA may serve as a rapid and highly sensitive alternative for RSV diagnostics.",10.1371/journal.pone.0001357,3xab3yxc,"['The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'the', 'usability', 'of', 'three', 'diagnostic', 'procedures', 'for', 'the', 'detection', 'of', 'respiratory', 'syncytial', 'virus', 'in', 'clinical', 'samples', 'Therefore', 'the', 'FDA', 'cleared', 'CE', 'marked', 'NOW', 'RSV', 'ELISA', 'the', 'NucliSENS', 'EasyQ', 'RSV', 'A', 'B', 'NASBA', 'and', 'a', 'literature', 'based', 'inhouse', 'RT', 'PCR', 'protocol', 'were', 'compared', 'for', 'their', 'relative', 'sensitivities', 'Thereby', 'NASBA', 'turned', 'out', 'to', 'be', 'the', 'most', 'sensitive', 'method', 'with', 'a', 'total', 'number', 'of', '80', 'RSV', 'positive', 'samples', 'out', 'of', 'a', 'cohort', 'of', '251', 'nasopharyngeal', 'washings', 'from', 'patients', 'suffering', 'from', 'clinical', 'symptoms', 'followed', 'by', 'the', 'inhouse', 'RT', 'PCR', '62', '251', 'and', 'ELISA', '52', '251', 'Thus', 'NASBA', 'may', 'serve', 'as', 'a', 'rapid', 'and', 'highly', 'sensitive', 'alternative', 'for', 'RSV', 'diagnostics', '']"
145336,The sensitivity of respiratory tract specimens for the detection of SARS-CoV-2: A protocol for a living systematic review and meta-analysis,2020-07-04,medRxiv,https://www.ncbi.nlm.nih.gov/pubmed/32637978/; https://doi.org/10.1101/2020.07.02.20144543; http://medrxiv.org/cgi/content/short/2020.07.02.20144543v1?rss=1,"BACKGROUND: Highly sensitive, non-invasive, and easily accessible diagnostics for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are essential for the control of the Coronavirus Disease 2019 (COVID-19) pandemic. There is a clear need to establish a gold standard diagnostic for SARS-CoV-2 infection in humans using respiratory tract specimens. METHODS: Searches will be conducted in the bibliographic databases Medline, Embase, bioRxiv, medRxiv, F1000, ChemRxiv, PeerJ Preprints, Preprints.org, Beilstein Archive, and Research Square. Relevant government documents and grey literature will be sought on the FDA’s Emergency Use Authorizations website, the ECDC’s website, and the website of the Foundation for Innovative New Diagnostics. Finally, papers categorized as diagnosis papers by the EPPI Centre’s COVID-19 living systematic map will be added to our screening process; those papers are tagged with the diagnosis topic based on human review, rather than database searches, and thus this set of papers might include ones that have not been captured by our search strategy.",10.1101/2020.07.02.20144543,9afukke4,"['BACKGROUND', 'Highly', 'sensitive', 'non', 'invasive', 'and', 'easily', 'accessible', 'diagnostics', 'for', 'Severe', 'Acute', 'Respiratory', 'Syndrome', 'Coronavirus', '2', 'SARS', 'CoV', '2', 'are', 'essential', 'for', 'the', 'control', 'of', 'the', 'Coronavirus', 'Disease', '2019', 'COVID', '19', 'pandemic', 'There', 'is', 'a', 'clear', 'need', 'to', 'establish', 'a', 'gold', 'standard', 'diagnostic', 'for', 'SARS', 'CoV', '2', 'infection', 'in', 'humans', 'using', 'respiratory', 'tract', 'specimens', 'METHODS', 'Searches', 'will', 'be', 'conducted', 'in', 'the', 'bibliographic', 'databases', 'Medline', 'Embase', 'bioRxiv', 'medRxiv', 'F1000', 'ChemRxiv', 'PeerJ', 'Preprints', 'Preprints', 'org', 'Beilstein', 'Archive', 'and', 'Research', 'Square', 'Relevant', 'government', 'documents', 'and', 'grey', 'literature', 'will', 'be', 'sought', 'on', 'the', 'FDA', 's', 'Emergency', 'Use', 'Authorizations', 'website', 'the', 'ECDC', 's', 'website', 'and', 'the', 'website', 'of', 'the', 'Foundation', 'for', 'Innovative', 'New', 'Diagnostics', 'Finally', 'papers', 'categorized', 'as', 'diagnosis', 'papers', 'by', 'the', 'EPPI', 'Centre', 's', 'COVID', '19', 'living', 'systematic', 'map', 'will', 'be', 'added', 'to', 'our', 'screening', 'process', 'those', 'papers', 'are', 'tagged', 'with', 'the', 'diagnosis', 'topic', 'based', 'on', 'human', 'review', 'rather', 'than', 'database', 'searches', 'and', 'thus', 'this', 'set', 'of', 'papers', 'might', 'include', 'ones', 'that', 'have', 'not', 'been', 'captured', 'by', 'our', 'search', 'strategy', '']"
164112,Molecular detection and point-of-care testing in Ebola virus disease and other threats: a new global public health framework to stop outbreaks,2015-09-14,Expert Rev Mol Diagn,https://doi.org/10.1586/14737159.2015.1079776; https://www.ncbi.nlm.nih.gov/pubmed/26367243/,"Ultrahigh sensitivity and specificity assays that detect Ebola virus disease or other highly contagious and deadly diseases quickly and successfully upstream in Spatial Care Paths™ can stop outbreaks from escalating into devastating epidemics ravaging communities locally and countries globally. Even had the WHO and CDC responded more quickly and not misjudged the dissemination of Ebola in West Africa and other world regions, mobile rapid diagnostics were, and still are, not readily available for immediate and definitive diagnosis, a stunning strategic flaw that needs correcting worldwide. This article strategizes point-of-care testing for diagnosis, triage, monitoring, recovery and stopping outbreaks in the USA and other countries; reviews Ebola molecular diagnostics, summarizes USA FDA emergency use authorizations and documents why they should not be stop-gaps; and reduces community risk from internal and external infectious disease threats by enabling public health at points of need.",10.1586/14737159.2015.1079776,3wsihzhk,"['Ultrahigh', 'sensitivity', 'and', 'specificity', 'assays', 'that', 'detect', 'Ebola', 'virus', 'disease', 'or', 'other', 'highly', 'contagious', 'and', 'deadly', 'diseases', 'quickly', 'and', 'successfully', 'upstream', 'in', 'Spatial', 'Care', 'Paths', 'can', 'stop', 'outbreaks', 'from', 'escalating', 'into', 'devastating', 'epidemics', 'ravaging', 'communities', 'locally', 'and', 'countries', 'globally', 'Even', 'had', 'the', 'WHO', 'and', 'CDC', 'responded', 'more', 'quickly', 'and', 'not', 'misjudged', 'the', 'dissemination', 'of', 'Ebola', 'in', 'West', 'Africa', 'and', 'other', 'world', 'regions', 'mobile', 'rapid', 'diagnostics', 'were', 'and', 'still', 'are', 'not', 'readily', 'available', 'for', 'immediate', 'and', 'definitive', 'diagnosis', 'a', 'stunning', 'strategic', 'flaw', 'that', 'needs', 'correcting', 'worldwide', 'This', 'article', 'strategizes', 'point', 'of', 'care', 'testing', 'for', 'diagnosis', 'triage', 'monitoring', 'recovery', 'and', 'stopping', 'outbreaks', 'in', 'the', 'USA', 'and', 'other', 'countries', 'reviews', 'Ebola', 'molecular', 'diagnostics', 'summarizes', 'USA', 'FDA', 'emergency', 'use', 'authorizations', 'and', 'documents', 'why', 'they', 'should', 'not', 'be', 'stop', 'gaps', 'and', 'reduces', 'community', 'risk', 'from', 'internal', 'and', 'external', 'infectious', 'disease', 'threats', 'by', 'enabling', 'public', 'health', 'at', 'points', 'of', 'need', '']"
177963,FDA Perspectives on Diagnostic Device Clinical Studies for Respiratory Infections,2011-05-01,Clin Infect Dis,https://www.ncbi.nlm.nih.gov/pubmed/21460289/; https://doi.org/10.1093/cid/cir056,"Two pathways are described for submission to FDA for clearance of a diagnostic device: a Premarket Application (PMA), which can lead to approval of a diagnostic device, and a Premarket Notification, which can lead to clearance. The latter is often called a 510(k), named for the statute providing for this path. Recent FDA clearance of molecular-based multiplex panels represents the beginning of a new era for the diagnosis of respiratory infections. The ability to test for multiple pathogens simultaneously, accompanied by the increasing availability of molecular-based assays for newly recognized respiratory pathogens will likely have a major impact on patient care, drug development, and public health epidemiology. We provide a general overview of how FDA evaluates new diagnostics for respiratory tract infections and the agency’s expectations for sponsors developing new tests in this area.",10.1093/cid/cir056,uijwq8gx,"['Two', 'pathways', 'are', 'described', 'for', 'submission', 'to', 'FDA', 'for', 'clearance', 'of', 'a', 'diagnostic', 'device', 'a', 'Premarket', 'Application', 'PMA', 'which', 'can', 'lead', 'to', 'approval', 'of', 'a', 'diagnostic', 'device', 'and', 'a', 'Premarket', 'Notification', 'which', 'can', 'lead', 'to', 'clearance', 'The', 'latter', 'is', 'often', 'called', 'a', '510', 'k', 'named', 'for', 'the', 'statute', 'providing', 'for', 'this', 'path', 'Recent', 'FDA', 'clearance', 'of', 'molecular', 'based', 'multiplex', 'panels', 'represents', 'the', 'beginning', 'of', 'a', 'new', 'era', 'for', 'the', 'diagnosis', 'of', 'respiratory', 'infections', 'The', 'ability', 'to', 'test', 'for', 'multiple', 'pathogens', 'simultaneously', 'accompanied', 'by', 'the', 'increasing', 'availability', 'of', 'molecular', 'based', 'assays', 'for', 'newly', 'recognized', 'respiratory', 'pathogens', 'will', 'likely', 'have', 'a', 'major', 'impact', 'on', 'patient', 'care', 'drug', 'development', 'and', 'public', 'health', 'epidemiology', 'We', 'provide', 'a', 'general', 'overview', 'of', 'how', 'FDA', 'evaluates', 'new', 'diagnostics', 'for', 'respiratory', 'tract', 'infections', 'and', 'the', 'agency', 's', 'expectations', 'for', 'sponsors', 'developing', 'new', 'tests', 'in', 'this', 'area', '']"
191056,"Life beyond PCR: alternative target amplification technologies for the diagnosis of infectious diseases, part I 1 1 Editor's Note: Part II of this article will be published in the September 1 issue of CMN (vol. 26, no. 17).",2004-08-15,Clinical Microbiology Newsletter,https://api.elsevier.com/content/article/pii/S0196439904000297; https://doi.org/10.1016/j.clinmicnews.2004.08.001; https://www.ncbi.nlm.nih.gov/pubmed/32287673/; https://www.sciencedirect.com/science/article/pii/S0196439904000297,"Abstract Non-PCR-based target amplification technologies, including transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), and strand displacement amplification (SDA), are currently the basis for a broad range of clinical infectious-disease molecular diagnostics. These amplification technologies are very sensitive and specific and can be used in combination with traditional end-point or “real-time” detection formats. For several nucleic acid targets, TMA, NASBA, and SDA have certain advantages over PCR-based applications. This two-part article will review the molecular basis of each technology and how the technology has been applied to clinical diagnostic systems. The articles will describe the current testing platforms available, U.S. Food and Drug Administration (FDA)- and non-FDA-approved assays, and availability of analyte-specific reagents. In addition, an open-platform system is described that utilizes standardized reagents and methods and allows the user to develop in-house protocols. Finally, applications for the future are discussed.",10.1016/j.clinmicnews.2004.08.001,j33pov9p,"['Abstract', 'Non', 'PCR', 'based', 'target', 'amplification', 'technologies', 'including', 'transcription', 'mediated', 'amplification', 'TMA', 'nucleic', 'acid', 'sequence', 'based', 'amplification', 'NASBA', 'and', 'strand', 'displacement', 'amplification', 'SDA', 'are', 'currently', 'the', 'basis', 'for', 'a', 'broad', 'range', 'of', 'clinical', 'infectious', 'disease', 'molecular', 'diagnostics', 'These', 'amplification', 'technologies', 'are', 'very', 'sensitive', 'and', 'specific', 'and', 'can', 'be', 'used', 'in', 'combination', 'with', 'traditional', 'end', 'point', 'or', 'real', 'time', 'detection', 'formats', 'For', 'several', 'nucleic', 'acid', 'targets', 'TMA', 'NASBA', 'and', 'SDA', 'have', 'certain', 'advantages', 'over', 'PCR', 'based', 'applications', 'This', 'two', 'part', 'article', 'will', 'review', 'the', 'molecular', 'basis', 'of', 'each', 'technology', 'and', 'how', 'the', 'technology', 'has', 'been', 'applied', 'to', 'clinical', 'diagnostic', 'systems', 'The', 'articles', 'will', 'describe', 'the', 'current', 'testing', 'platforms', 'available', 'U', 'S', 'Food', 'and', 'Drug', 'Administration', 'FDA', 'and', 'non', 'FDA', 'approved', 'assays', 'and', 'availability', 'of', 'analyte', 'specific', 'reagents', 'In', 'addition', 'an', 'open', 'platform', 'system', 'is', 'described', 'that', 'utilizes', 'standardized', 'reagents', 'and', 'methods', 'and', 'allows', 'the', 'user', 'to', 'develop', 'in', 'house', 'protocols', 'Finally', 'applications', 'for', 'the', 'future', 'are', 'discussed', '']"
196831,"The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics",2018-06-22,Respir Res,https://www.ncbi.nlm.nih.gov/pubmed/29929556/; https://doi.org/10.1186/s12931-018-0784-1,"The Human Viral Challenge (HVC) model has, for many decades, helped in the understanding of respiratory viruses and their role in disease pathogenesis. In a controlled setting using small numbers of volunteers removed from community exposure to other infections, this experimental model enables proof of concept work to be undertaken on novel therapeutics, including vaccines, immunomodulators and antivirals, as well as new diagnostics. Crucially, unlike conventional phase 1 studies, challenge studies include evaluable efficacy endpoints that then guide decisions on how to optimise subsequent field studies, as recommended by the FDA and thus licensing studies that follow. Such a strategy optimises the benefit of the studies and identifies possible threats early on, minimising the risk to subsequent volunteers but also maximising the benefit of scarce resources available to the research group investing in the research. Inspired by the principles of the 3Rs (Replacement, Reduction and Refinement) now commonly applied in the preclinical phase, HVC studies allow refinement and reduction of the subsequent development phase, accelerating progress towards further statistically powered phase 2b studies. The breadth of data generated from challenge studies allows for exploration of a wide range of variables and endpoints that can then be taken through to pivotal phase 3 studies. We describe the disease burden for acute respiratory viral infections for which current conventional development strategies have failed to produce therapeutics that meet clinical need. The Authors describe the HVC model’s utility in increasing scientific understanding and in progressing promising therapeutics through development. The contribution of the model to the elucidation of the virus-host interaction, both regarding viral pathogenicity and the body’s immunological response is discussed, along with its utility to assist in the development of novel diagnostics. Future applications of the model are also explored. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12931-018-0784-1) contains supplementary material, which is available to authorized users.",10.1186/s12931-018-0784-1,n026zwp8,"['The', 'Human', 'Viral', 'Challenge', 'HVC', 'model', 'has', 'for', 'many', 'decades', 'helped', 'in', 'the', 'understanding', 'of', 'respiratory', 'viruses', 'and', 'their', 'role', 'in', 'disease', 'pathogenesis', 'In', 'a', 'controlled', 'setting', 'using', 'small', 'numbers', 'of', 'volunteers', 'removed', 'from', 'community', 'exposure', 'to', 'other', 'infections', 'this', 'experimental', 'model', 'enables', 'proof', 'of', 'concept', 'work', 'to', 'be', 'undertaken', 'on', 'novel', 'therapeutics', 'including', 'vaccines', 'immunomodulators', 'and', 'antivirals', 'as', 'well', 'as', 'new', 'diagnostics', 'Crucially', 'unlike', 'conventional', 'phase', '1', 'studies', 'challenge', 'studies', 'include', 'evaluable', 'efficacy', 'endpoints', 'that', 'then', 'guide', 'decisions', 'on', 'how', 'to', 'optimise', 'subsequent', 'field', 'studies', 'as', 'recommended', 'by', 'the', 'FDA', 'and', 'thus', 'licensing', 'studies', 'that', 'follow', 'Such', 'a', 'strategy', 'optimises', 'the', 'benefit', 'of', 'the', 'studies', 'and', 'identifies', 'possible', 'threats', 'early', 'on', 'minimising', 'the', 'risk', 'to', 'subsequent', 'volunteers', 'but', 'also', 'maximising', 'the', 'benefit', 'of', 'scarce', 'resources', 'available', 'to', 'the', 'research', 'group', 'investing', 'in', 'the', 'research', 'Inspired', 'by', 'the', 'principles', 'of', 'the', '3Rs', 'Replacement', 'Reduction', 'and', 'Refinement', 'now', 'commonly', 'applied', 'in', 'the', 'preclinical', 'phase', 'HVC', 'studies', 'allow', 'refinement', 'and', 'reduction', 'of', 'the', 'subsequent', 'development', 'phase', 'accelerating', 'progress', 'towards', 'further', 'statistically', 'powered', 'phase', '2b', 'studies', 'The', 'breadth', 'of', 'data', 'generated', 'from', 'challenge', 'studies', 'allows', 'for', 'exploration', 'of', 'a', 'wide', 'range', 'of', 'variables', 'and', 'endpoints', 'that', 'can', 'then', 'be', 'taken', 'through', 'to', 'pivotal', 'phase', '3', 'studies', 'We', 'describe', 'the', 'disease', 'burden', 'for', 'acute', 'respiratory', 'viral', 'infections', 'for', 'which', 'current', 'conventional', 'development', 'strategies', 'have', 'failed', 'to', 'produce', 'therapeutics', 'that', 'meet', 'clinical', 'need', 'The', 'Authors', 'describe', 'the', 'HVC', 'model', 's', 'utility', 'in', 'increasing', 'scientific', 'understanding', 'and', 'in', 'progressing', 'promising', 'therapeutics', 'through', 'development', 'The', 'contribution', 'of', 'the', 'model', 'to', 'the', 'elucidation', 'of', 'the', 'virus', 'host', 'interaction', 'both', 'regarding', 'viral', 'pathogenicity', 'and', 'the', 'body', 's', 'immunological', 'response', 'is', 'discussed', 'along', 'with', 'its', 'utility', 'to', 'assist', 'in', 'the', 'development', 'of', 'novel', 'diagnostics', 'Future', 'applications', 'of', 'the', 'model', 'are', 'also', 'explored', 'ELECTRONIC', 'SUPPLEMENTARY', 'MATERIAL', 'The', 'online', 'version', 'of', 'this', 'article', '10', '1186', 's12931', '018', '0784', '1', 'contains', 'supplementary', 'material', 'which', 'is', 'available', 'to', 'authorized', 'users', '']"
204163,Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape,2020-07-18,Biosens Bioelectron,https://www.sciencedirect.com/science/article/pii/S0956566320304486?v=s5; https://doi.org/10.1016/j.bios.2020.112454; https://api.elsevier.com/content/article/pii/S0956566320304486,"The rapidly spreading outbreak of COVID-19 disease is caused by the SARS-CoV-2 virus, first reported in December 2019 in Wuhan, China. As of June 17, 2020, this virus has infected over 8.2 million people but ranges in symptom severity, making it difficult to assess its overall infection rate. There is a need for rapid and accurate diagnostics to better monitor and prevent the spread of COVID-19. In this review, we present and evaluate two main types of diagnostics with FDA-EUA status for COVID-19: nucleic acid testing for detection of SARS-CoV-2 RNA, and serological assays for detection of SARS-CoV-2 specific IgG and IgM patient antibodies, along with the necessary sample preparation for accurate diagnoses. In particular, we cover and compare tests such as the CDC 2019-nCoV RT-PCR Diagnostic Panel, Cellex's qSARS-CoV-2 IgG/IgM Rapid Test, and point-of-care tests such as Abbott's ID NOW COVID-19 Test. Antibody testing is especially important in understanding the prevalence of the virus in the community and to identify those who have gained immunity. We conclude by highlighting the future of COVID-19 diagnostics, which include the need for quantitative testing and the development of emerging biosensors as point-of-care tests.",10.1016/j.bios.2020.112454,3ejychjf,"['The', 'rapidly', 'spreading', 'outbreak', 'of', 'COVID', '19', 'disease', 'is', 'caused', 'by', 'the', 'SARS', 'CoV', '2', 'virus', 'first', 'reported', 'in', 'December', '2019', 'in', 'Wuhan', 'China', 'As', 'of', 'June', '17', '2020', 'this', 'virus', 'has', 'infected', 'over', '8', '2', 'million', 'people', 'but', 'ranges', 'in', 'symptom', 'severity', 'making', 'it', 'difficult', 'to', 'assess', 'its', 'overall', 'infection', 'rate', 'There', 'is', 'a', 'need', 'for', 'rapid', 'and', 'accurate', 'diagnostics', 'to', 'better', 'monitor', 'and', 'prevent', 'the', 'spread', 'of', 'COVID', '19', 'In', 'this', 'review', 'we', 'present', 'and', 'evaluate', 'two', 'main', 'types', 'of', 'diagnostics', 'with', 'FDA', 'EUA', 'status', 'for', 'COVID', '19', 'nucleic', 'acid', 'testing', 'for', 'detection', 'of', 'SARS', 'CoV', '2', 'RNA', 'and', 'serological', 'assays', 'for', 'detection', 'of', 'SARS', 'CoV', '2', 'specific', 'IgG', 'and', 'IgM', 'patient', 'antibodies', 'along', 'with', 'the', 'necessary', 'sample', 'preparation', 'for', 'accurate', 'diagnoses', 'In', 'particular', 'we', 'cover', 'and', 'compare', 'tests', 'such', 'as', 'the', 'CDC', '2019', 'nCoV', 'RT', 'PCR', 'Diagnostic', 'Panel', 'Cellex', 's', 'qSARS', 'CoV', '2', 'IgG', 'IgM', 'Rapid', 'Test', 'and', 'point', 'of', 'care', 'tests', 'such', 'as', 'Abbott', 's', 'ID', 'NOW', 'COVID', '19', 'Test', 'Antibody', 'testing', 'is', 'especially', 'important', 'in', 'understanding', 'the', 'prevalence', 'of', 'the', 'virus', 'in', 'the', 'community', 'and', 'to', 'identify', 'those', 'who', 'have', 'gained', 'immunity', 'We', 'conclude', 'by', 'highlighting', 'the', 'future', 'of', 'COVID', '19', 'diagnostics', 'which', 'include', 'the', 'need', 'for', 'quantitative', 'testing', 'and', 'the', 'development', 'of', 'emerging', 'biosensors', 'as', 'point', 'of', 'care', 'tests', '']"
